close
close
close
EU GMP Annex 1 is driving the reevaluation of key processes in aseptic processing. For manufacturers, this means that existing plant designs, setup procedures, and operations within isolators must be reviewed for regulatory compliance and realigned, as well as assessed and documented as part of a Contamination Control Strategy (CCS).
In many aseptic systems, processes rely on a fully bio-decontaminated environment, supplemented by manual interventions via isolator gloves. Annex 1 sets new standards by requiring sterile introduction of direct and indirect product-contact materials and components into the isolator before production. Bio-decontamination alone is no longer sufficient. As a matter of principle, glove interventions in the isolator are considered critical, and direct handling of product-contact components is no longer permitted. In addition, Annex 1 requires an undisturbed, unidirectional airflow to all critical areas (First Air at working position). Necessary interventions must be evaluated and documented in a CCS, and components that affect the First Air must be autoclaved prior to introduction. Compliance with Annex 1 requirements alters the assessment of existing set-up and processing procedures and often necessitate technical adjustments to plant designs and workflows.
Components that come into direct or indirect contact with the product are autoclaved externally before being transferred into a pre-biodecontaminated environment via defined sterile transfer systems such as RTP ports or material transfer locks. Consequently, the setup process must be designed to minimize manual handling as much as possible. Tasks that were previously performed using isolator gloves are increasingly handled by automated or mechanically assisted solutions. Sensitive assemblies, such as the fill path (parts in direct contact with the product), pose particularly high requirements; their installation must be designed to reliably prevent direct glove contact.
These technical approaches specifically reduce contamination risks and make setup and production processes safer and more reproducible. Critical unplanned interventions, such as those involving plug interventions or procedures conducted as part of environmental monitoring, can be significantly reduced or avoided through appropriately developed technical solutions. This creates pharmaceutical processes that are robust, safe, and consistently aligned with regulatory requirements.
Optima translates these requirements into practical plant designs, including isolator systems with integrated sterile transfer, automated setup solutions, and plant designs tailored to First Air. This ensures the systematic implementation of Annex 1 requirements while enhancing process reliability and efficiency.
